Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 18;23(1):673.
doi: 10.1186/s12885-023-11117-5.

Prognostic value of EBV DNA and platelet-to-lymphocyte ratio in patients with non-metastatic nasopharyngeal carcinoma: a retrospective study

Huan Dong #  1   2 , Zichong Huang #  1   3 , Dong Yang  1 , Zhiru Li  1 , Heqing Huang  1 , Zhen Meng  1 , Yutao Qin  4 , Min Kang  5
Affiliations

Prognostic value of EBV DNA and platelet-to-lymphocyte ratio in patients with non-metastatic nasopharyngeal carcinoma: a retrospective study

Huan Dong et al. BMC Cancer. .

Abstract

Purpose: Analyzing the prognostic value of Epstein-Barr virus (EBV) DNA load and platelet-to-lymphocyte ratio (PLR) in non-metastatic nasopharyngeal carcinoma (NPC) patients, thereby developing a reliable and effective marker.

Methods: We compared survival rates among different groups using the Kaplan-Meier method and the Log-rank test. The factors affecting the prognosis of NPC patients were determined using univariate and multivariate cox regression analysis. Receiver operating characteristic (ROC) curves were used to identify the cutoff-value and discriminant performance of the model.

Results: The ROC curve indicated a cut-off value of 775 copies/ml for EBV DNA and 203.3 for PLR. Kaplan-Meier and Log-rank tests showed that 3-year overall survival (OS), local recurrence-free survival (LRFS) and distant metastasis-free survival (DMFS) of NPC patients in high risk group (HRG) were significantly poorer than those in medium risk group (MRG) and low risk group (LRG). The 3-year OS of NPC patients was significantly correlated with age, N stage and EBV DNA-PLR. The 3-year LRFS were significantly correlated with sex, N stage, histology type, and EBV DNA-PLR. The 3-year DMFS were correlated with histology type. The ROC curve showed that area under the curve (AUC) values of EBV DNA-PLR of 3-year OS, LRFS and DMFS in NPC were higher than those of PLR and EBV DNA.

Conclusion: EBV DNA-PLR is an independent risk factor for the prognosis of NPC. Compared with PLR or EBV DNA alone, the combination of EBV DNA and PLR may be more accurate in predicting the prognosis of NPC patients.

Keywords: Epstein-Barr virus DNA; Nasopharyngeal carcinoma; Platelet-to-lymphocyte ratio; Prognosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Kaplan-Meier survival curves of 3-year OS (A), LRFS (B) and DMFS (C) in LRG, MRG and HRG. Abbreviations: OS, overall survival; LRFS, local recurrence-free survival; DMFS, distant metastasis-free survival; LRG, low risk group; MRG, medium risk group; HRG, high risk group
Fig. 2
Fig. 2
Kaplan-Meier survival curves of 3-year OS (A), LRFS (B) and DMFS (C) in different EBV DNA levels(< 775 vs.> 775) Abbreviations: OS, overall survival; LRFS, local recurrence-free survival; DMFS, distant metastasis-free survival
Fig. 3
Fig. 3
Kaplan-Meier survival curves of 3-year OS (A), LRFS (B) and DMFS (C) in different PLR levels(< 203.3 vs.> 203.3) Abbreviations: OS, overall survival; LRFS, local recurrence-free survival; DMFS, distant metastasis-free survival
Fig. 4
Fig. 4
ROC curves for EBV DNA-PLR, PLR, EBV DNA and Overall stage of 3-year OS (A), LRFS (B), DMFS (C) Abbreviations: EBV, Epstein-Barr virus; PLR, platelet-to-lymphocyte ratio; OS, overall survival; LRFS, local recurrence-free survival; DMFS, distant metastasis-free survival; ROC, receiver operating characteristic
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Chen YP, Chan A, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019;394(10192):64–80. doi: 10.1016/S0140-6736(19)30956-0. - DOI - PubMed
    1. Chan AT, Teo PM, Ngan RK, Leung TW, Lau WH, Zee B, et al. Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol. 2002;20(8):2038–44. doi: 10.1200/JCO.2002.08.149. - DOI - PubMed
    1. Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The Eighth Edition AJCC Cancer staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–9. doi: 10.3322/caac.21388. - DOI - PubMed
    1. Tang LL, Chen YP, Mao YP, Wang ZX, Guo R, Chen L, et al. Validation of the 8th Edition of the UICC/AJCC staging system for nasopharyngeal carcinoma from endemic areas in the intensity-modulated Radiotherapy Era. J Natl Compr Canc Netw. 2017;15(7):913–9. doi: 10.6004/jnccn.2017.0121. - DOI - PubMed
    1. OuYang PY, Su Z, Ma XH, Mao YP, Liu MZ, Xie FY. Comparison of TNM staging systems for nasopharyngeal carcinoma, and proposal of a new staging system. Br J Cancer. 2013;109(12):2987–97. doi: 10.1038/bjc.2013.659. - DOI - PMC - PubMed

LinkOut - more resources